What is HC Wainwright's Estimate for ANIP Q2 Earnings?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - HC Wainwright issued their Q2 2025 earnings estimates for ANI Pharmaceuticals in a research report issued to clients and investors on Thursday, July 10th. HC Wainwright analyst B. Folkes expects that the specialty pharmaceutical company will earn $1.02 per share for the quarter. HC Wainwright has a "Buy" rating and a $84.00 price target on the stock. The consensus estimate for ANI Pharmaceuticals' current full-year earnings is $3.86 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals' Q3 2025 earnings at $1.13 EPS, Q4 2025 earnings at $1.40 EPS, FY2025 earnings at $4.94 EPS and FY2026 earnings at $5.64 EPS.

Other equities research analysts have also issued research reports about the stock. Guggenheim restated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Finally, Truist Financial raised their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $78.88.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded up $1.44 during trading hours on Monday, hitting $68.04. The stock had a trading volume of 401,195 shares, compared to its average volume of 319,161. The stock's fifty day simple moving average is $62.88 and its 200 day simple moving average is $62.58. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $77.00. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -53.57 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.98 and a current ratio of 2.66.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The company had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same quarter last year, the business earned $0.82 earnings per share. ANI Pharmaceuticals's revenue was up 43.4% compared to the same quarter last year.

Institutional Trading of ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue boosted its holdings in ANI Pharmaceuticals by 10.0% during the second quarter. State of Alaska Department of Revenue now owns 10,116 shares of the specialty pharmaceutical company's stock worth $659,000 after buying an additional 920 shares in the last quarter. Voya Investment Management LLC boosted its holdings in ANI Pharmaceuticals by 12.0% during the first quarter. Voya Investment Management LLC now owns 8,934 shares of the specialty pharmaceutical company's stock worth $598,000 after buying an additional 957 shares in the last quarter. Jane Street Group LLC bought a new stake in ANI Pharmaceuticals during the first quarter worth approximately $2,706,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock worth $3,235,000 after buying an additional 423 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in ANI Pharmaceuticals during the first quarter worth approximately $11,144,000. 76.05% of the stock is currently owned by institutional investors.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Ori Gutwerg sold 881 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the transaction, the senior vice president owned 89,897 shares in the company, valued at $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christopher Mutz sold 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the transaction, the insider owned 107,317 shares in the company, valued at $6,487,312.65. This represents a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,681 shares of company stock worth $345,222 over the last quarter. 11.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.